Molecular structure of Vinpocetine, CAS Number: 42971-09-5
Vinpocetine (CAS 42971-09-5)
See product citations (4)
Alternate Names:
ethyl apovincaminate
Application:
Vinpocetine is an inhibitor of Ca2+/CaM-PDE with neuroprotective properties
CAS Number:
42971-09-5
Purity:
≥98%
Molecular Weight:
350.45
Molecular Formula:
C22H26N2O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Vinpocetine, a synthetic derivative of the minor alkaloid vincarmine from the Vinca genus of plants, is a cyclic nucleotide Ca2+-dependent/calmodulin-stimulated phosphodiesterase (PDE) inhibitor. Studies suggest that Vinpocetine′s selective inhibition of PDE1 (CaM-PDE ) may induce vascular relaxation by increasing cyclic GMP contents in vascular smooth muscle. Research has shown that Vinpocetine could exert a neuroprotective type of action in vivo. Specifically, Vinpocetine has been found to display a capacity to effectively attenuate behavioral deficits caused by lesions in rat brains and decrease the region of microglia activation.
Vinpocetine (CAS 42971-09-5) References
- Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. | Nyakas, C., et al. 2009. CNS Neurosci Ther. 15: 89-99. PMID: 19492990
- Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. | Vohora, D., et al. 2010. Drugs Today (Barc). 46: 265-77. PMID: 20502724
- Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. | Ahn, HS., et al. 1989. Biochem Pharmacol. 38: 3331-9. PMID: 2554921
- Vinpocetine represses the progression of nonalcoholic steatohepatitis in mice by mediating inflammasome components via NF-κB signaling. | Zhu, Y., et al. 2024. Gastroenterol Hepatol. 47: 366-376. PMID: 37562770
- Effect of vinpocetine against acrylamide-induced nephrotoxicity in rats. | Ibrahim, DS. 2024. J Biochem Mol Toxicol. 38: e23658. PMID: 38348719
- Synthesis and pharmacological activity of vinpocetine derivatives. | Dong, ZC., et al. 2024. RSC Adv. 14: 7981-7991. PMID: 38454939
- Vinpocetine attenuates methotrexate-induced hippocampal intoxication via Keap-1/Nrf2, NF-κB/AP-1, and apoptotic pathways in rats. | Alghamdi, B., et al. 2024. Drug Chem Toxicol. 1-12. PMID: 38508707
- Regulation of cerebral blood flow boosts precise brain targeting of vinpocetine-derived ionizable-lipidoid nanoparticles. | Bian, X., et al. 2024. Nat Commun. 15: 3987. PMID: 38734698
- The ameliorative effect of vinpocetine against gentamicin-induced uterine-injury in rats involves the inflammasome/caspase-1/IL-1β pathway. | Geddawy, A., et al. 2024. Mol Biol Rep. 51: 655. PMID: 38739285
- Vinpocetine alleviated alveolar epithelial cells injury in experimental pulmonary fibrosis by targeting PPAR-γ/NLRP3/NF-κB and TGF-β1/Smad2/3 pathways. | Hussein, ZA., et al. 2024. Sci Rep. 14: 11131. PMID: 38750140
- Enantiospecific crystallisation behaviour of malic acid in mechanochemical reactions with vinpocetine. | D'Abbrunzo, I., et al. 2024. Eur J Pharm Biopharm. 114344. PMID: 38815873
- First report on the electrooxidation of vinpocetine using a modification free sensing platform: application to pharmaceutical formulations. | Silva Lima, AR., et al. 2024. Anal Methods. 16: 4002-4009. PMID: 38855859
- The anti-inflammatory properties of vinpocetine mediates its therapeutic potential in management of atherosclerosis. | Alshehri, AA., et al. 2024. J Inflamm (Lond). 21: 19. PMID: 38858751
- Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. | Hagiwara, M., et al. 1984. Biochem Pharmacol. 33: 453-7. PMID: 6322804
Inhibitor of:
CNBD2, GPR161, Guanylate Cyclase (GUCA), L-Selectin, Olfr1031, Olfr1036, Olfr1065, Olfr107, Olfr1178, Olfr739, Olr483, PDE, PDE1A, PDE1B, PDE1C, PDE6Aα, PDE6D, PDE7B, PDE8B, and PED7A.Activator of:
α N-catenin, α-protein kinase 3, 1110008L16Rik, 2′-PDE, A330021E22Rik, AKAP 12, AKAP 150, APOBEC4, ARA160, ARL6, ARMC4, ATP6E, ATPBD4, Basonuclin 2, Bcl11a, C4BPα, CA VIII, cAMP-GEFII, CapZIP, CCDC114, CCDC85B, CELF6, CERKL, cGKII, CGREF1, CHCHD5, CINAP, CLCA5_Clac5, CLN5, CNBD1, CNG-β3, CNG-1, CNG-3, CNG-4, Cngb1, CNPase, COMMD6, connexin 36, COPE, cortistatin, CPSF, CREST, CRISP-2, CSDA, DCIR4, DUOXA2, Emi1, EPI64, Epsilon-COP, ESE-3A, ExoC3L, EXOSC9, FAM40B, FGF-13, GCC1, GIOT-3, GNL3L, Gucy2g, HCN2, HCN3, HCN4, HDHD2, HMGN3, HOP-1, KCTD21, KRTAP10-3, KV4.2, laeverin_4833403I15Rik, LAGE-3, LCA5, LHR, LLPH, LMBRD2, LRRC56, Ly6g, LZTFL1, MC2-R, MFF, MRP-L16, MSG1, MYLPF, nardilysin, NCCRP1, nephrocystin-4, Neuroplastin, NIFK, NOP9, Npcd, Olfr1018, Olfr1080, Olfr1090, Olfr301, OR2F1, OR4E2, OR4K14, OR4K5, OR5D16, OR5K1, OR8K1, Otospiralin, PCDHA10, PCTAIRE-3, PDE10A, PDE11A, PDE2A, PDE9A, PHACTR1, PHT2, PKA IIα reg, PKA IIβ reg, PPEF-1, Ppp1r3d, PPP1R3E, PPP1R3F, PPP1R3G, PRR18, Psf1, PTG, RAPGEF5, RBM3, RGS18, Rim2, RNase 13, Rpp25, RPS4YX, RSP3, SG2NA, SLC35D3, SLC38A9, SNAPC 190, SPACR, SV2B, Synapsin Ia, Synaptoporin, Syntaxin 1, t-GMP, TALK-2, TAPBPL, TBRG1, Tctex1D2, TMEM118, TMEM150B, TMEM86B, TMEM9B, TPPP, TSGA13, TTLL13, UNC-13, VAMP-1, Vmn1r-ps4, Vmn1r115, Vmn1r77, Vmn2r118, Vmn2r123, Vmn2r24, Vmn2r35, Vmn2r37, Vmn2r4, Vmn2r41, Vmn2r43, Vmn2r45, Vmn2r47, Vmn2r49, Vmn2r50, Vmn2r52, Vmn2r54, Vmn2r56, WDR73, WECHE, and YB-2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Vinpocetine, 20 mg | sc-201204 | 20 mg | $55.00 | |||
Vinpocetine, 100 mg | sc-201204A | 100 mg | $214.00 | |||
Vinpocetine, 15 g | sc-201204B | 15 g | $2400.00 |